Digest Network Come funziona
Network
/
Società
La
Non verificato

Lantern Pharma Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaOncologiaSaluteTecnica

72 comunicati stampa

Guarda tutti i comunicati
08/10/2026
Fiere
Eventi
Sanità
Software
Medicina nucleare
Farmaceutica
Attrezzature medico-sanitarie
Tecnica
Medicina - Varie
Biotecnologia
Igiene alimentare
Salute
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
07/10/2026
Industria
Scienza
Tecnica
Medicina - Varie
Biotecnologia
Farmaceutica
Salute
Oncologia
Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
30/09/2026
Finanza
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
29/09/2026
Finanza
Oncologia
Salute
Tecnica
Farmaceutica
Biotecnologia
Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
23/09/2026
Web e Social Network
Eventi
Scienza
Oncologia
Tecnica
Attrezzature medico-sanitarie
Biotecnologia
Medicina - Varie
Igiene alimentare
Salute
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
22/09/2026
Industria
Information Technology
Biotecnologia
Tecnica
Igiene alimentare
Salute
Farmaceutica
Oncologia
Scienza
Medicina - Varie
Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
17/09/2026
Software
Scienza
Farmaceutica
Oncologia
Information Technology
Tecnica
Biotecnologia
Medicina - Varie
Salute
Web e Social Network
Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
14/08/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Information Technology
Biotecnologia
Tecnica
Igiene alimentare
Sanità
Salute
Farmaceutica
Oncologia
Software
Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
07/08/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Scienza
Tecnica
Medicina - Varie
Biotecnologia
Farmaceutica
Salute
Oncologia
Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
03/08/2026
Industria
Information Technology
Sanità
Tecnica
Farmaceutica
Oncologia
Medicina - Varie
Tecnologie Varie
Scienza
Biotecnologia
Software
Salute
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0